NEUROSCIENCES
Neurology The neurology team at NSLHD has interest in a broad range of research, ranging from the laboratory to clinical research. The neurogenetics team has a proven track record of successful NHMRC grants, with research ranging from mitochondrial disorders to Parkinson’s disease. The unit has recently commenced a world-first placebo controlled drug trial in dominant optic atrophy, which is looking into a potential therapy for patients. If successful, the study has the potential to prevent visual loss and neurological signs such as deafness. The team’s stroke research is world class, with studies on clot busting and clot retrieval therapies. Our neurophysiology research has led to multiple prizes from academic institutes and includes some novel techniques not available elsewhere in the country. Migraine has recently become a major research interest, with novel international trials commencing at NSLHD. At NSLHD, the referral clinics for Parkinson’s disease and mitochondrial diseases are the largest in New South Wales and the multiple sclerosis clinic has one of the largest databases in Sydney. These clinics provide an opportunity to integrate research with clinical care by our teams of neurologists, trainees, nurses and allied health staff. This is of huge benefit to our patients who can receive world class care while provided the opportunity to take part in global studies. Key partners in this research include the University of Sydney, Macquarie University, NHMRC, MITO Foundation and many other colleagues, industry groups and supporters.
Key achievements to date include: › Lubomski, M., Davis, R.L. & Sue, C.M. Gastrointestinal dysfunction in Parkinson’s disease. J Neurol 267 , 1377–1388 (2020). https://doi.org/10.1007/s00415-020-09723-5 › Lubomski, M., Tan, A.H., Lim, SY. et al. Parkinson’s disease and the gastrointestinal microbiome. J Neurol 267 , 2507–2523 (2020). https://doi.org/10.1007/s00415-019- 09320-1 › Wali G, Liyanage E, Blair NF, Sutharsan R, Park JS, Mackay-Sim A, Sue CM. Oxidative Stress-Induced Axon Fragmentation Is a Consequence of Reduced Axonal Transport in Hereditary Spastic Paraplegia SPAST Patient Neurons. Front Neurosci. 2020 May 7;14:401. doi: 10.3389/fnins.2020.00401. PMID: 32457567; PMCID: PMC7221066 › Wali G, Kumar KR, Liyanage E, Davis RL, Mackay-Sim A, Sue CM. Mitochondrial Function in Hereditary Spastic Paraplegia: Deficits in SPG7 but Not SPAST Patient- Derived Stem Cells. Front Neurosci. 2020 Aug 20;14:820. doi: 10.3389/fnins.2020.00820. PMID: 32973427; PMCID: PMC7469654 › Whiten DR, Brownjohn PW, Moore S, De S, Strano A, Zuo Y, Haneklaus M, Klenerman D, Livesey FJ. Tumour necrosis factor induces increased production of extracellular amyloid-β- and α-synuclein- containing aggregates by human Alzheimer’s disease neurons. Brain Commun. 2020 Sep 15;2(2):fcaa146. doi: 10.1093/braincomms/ fcaa146. PMID: 33543132; PMCID: PMC7850285
40
RESEARCH ANNUAL REPORT 2020
Made with FlippingBook - professional solution for displaying marketing and sales documents online